TCT-26
Randomized Comparison Of Final Kissing Balloon Dilatation Versus No Final Kissing Balloon Dilatation In Patients With Coronary Bifurcation Lesions Treated With Main Vessel Stenting, Three Year Clinical Outcome In The Nordic-Baltic Bifurcation Study III

Niels R. Holm1, Kari Kervinen2, Matti J. Niemelä3, Andreja Erglis4, Indulas Kamara5, Terje Steigen6, Evald H. Christiansen7, Markku Eskola8, Hanna Rompanen9, Andis Dombrovskis1, Ole Frobert10, Lars Åberg11, Pål Gannes12, Jukka Ariukasinen13, Anders Hernfeld14, Sanda Jegere15, Thor Trovik16, Lisette Okkels Jensen17, Michael Maeng18, Timo Makkiland19, Mikko Pietila20, Ivar Siggren21, Per Thaysen22, Saila Villan23, Jen F. Lassen24, Leif Thuesen25, 1Aarhus University Hospital, Skejby, Aarhus N., Denmark, 2Oslo University Hospital, Oslo, Finland, 3University of Oulu, Oulu, Finland, 4Pauls Straudas Clinical University Hospital, Riga, Latvia, 5Lithuanian Cardiology Center, Riga, Latvia, 6University Hospital of Northern Norway, Tromso, Norway, 7Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus N., Denmark, 8Tampere Heart Center, Tampere, Finland, 9Lithuanian center of cardiology, Paul Straudas Clinical University Hospital, Riga, Latvia, 10Orebro University Hospital, Orebro, Sweden, 11Rikshospitalet, Oslo, Norway, 12Feiring klinikken, Feiring, Norway, 13Turku University Hospital, Turku, Finland, 14Pauls Straudas Clinical University Hospital, Riga, Not applicable, 15University Hospital of Tromsoe, Tromsoe, Norway, 16Odense University Hospital, Odense, Denmark, 17Aarhus University Hospital, Aarhus, Denmark, 18Falun Hospital, Falun, Sweden, 19Department of Cardiology, Odense University Hospital, Odense, Denmark, 20Tampere University Hospital, Tampere, Finland, 21Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, 22Aarhus, Denmark

Background: Using the recommended one-stent strategy for bifurcation treatment, a strategy of routine final kissing balloon dilation (FKBD) have resulted in longer and more complex procedures and mixed midterm clinical results as compared to a strategy of provisional FKBD. Delayed strut coverage, flow limiting neointimal growth on stent struts jailing the side branch ostium, but also stent distortion after FKBD, might affect long term clinical results. Here we present the 3-year clinical follow-up using the Nordic-Baltic Bifurcation Study III (NCT00914199) on routine vs. provisional FKBD.

Methods: We randomized 477 patients with a bifurcation lesion to FKBD (n=238) or no-FKBD (n=239) after main vessel stenting. The 6-month primary end-point was a composite of major adverse cardiac events (MACE), cardiac death, non-procedure related index lesion myocardial infarction, target lesion revascularization or stent thrombosis.

Results: No patients were lost to follow-up. The 36-month MACE rates were 9.7% vs. 10.0% (p=0.89) in the FKBD and no-FKBD groups, respectively. Total death was 5.9% vs. 2.1% (p=0.03), cardiac death was 2.1% vs. 0.4% (p=0.10), target lesion revascularization was 6.3% vs. 8.3% (p=0.39), and definite stent thrombosis was found in 0.8% vs. 1.3% (p=0.66) in the FKBD and no-FKBD groups, respectively. In the subgroup of true bifurcation lesions 36-month MACE rates were 9.1% in the FKBD group vs. 12.7% (p=0.37) in the no-FKBD group.

Conclusions: A strategy of routine FKBD compared to provisional FKBD in main vessel-only stenting did not improve 36-month clinical outcome after stenting of the main vessel in coronary bifurcation lesions.

TCT-27
The Impact of Second Generation Drug-eluting Stent on Mid-term Clinical Outcomes in Patients with Unprotected Left Main, Milan and New-Tokyo Registry

Kenzoaki Takagi1, Chiara Berneti2, Mauro Carlini3, Alaida Chieffo4, Antonio Colombo5, Yasuake Fujino6, Keiko Fukino6, Cosimo Godino7, Koji Hozawa8, Afonso Iela9, Hisakazu Ishiguro10, Hiroyoshi Kawamoto11, Naoyuki Kurita12, Azeem Latifi13, Takahiro Matsumoto3, Satoru Mitomo6, Matteo Montorfano7, Toru Naganuma14, Shotaro Nakamura6, Sunao Nakamura7, Satoko Tahara8, Takayuki Warisawa6, Yusuke Watanabe6, Hiroto Yabushita8, Niket Patel1, Derrick Bennett2, Kazem Rahimi2, Peter Ludman3, Adrian Banning4, Robert J. Gil1, Dobrin Vassilev2, Jacek Bil3, Luis A. Iñigo-García4, Azeem Latifi13, Takahiro Matsumoto6, Satoru Mitomo6, Matteo Montorfano7, Toru Naganuma14, Shotaro Nakamura6, Sunao Nakamura7, Satoko Tahara8, Takayuki Warisawa6, Yusuke Watanabe6, Hiroto Yabushita8

Background: Despite many studies concerning percutaneous coronary intervention (PCI) in patients with unprotected left main disease (ULM), there are a little data available regarding clinical outcomes between following 1st and 2nd generation drug eluting stent (DES) implantation.

Methods: Between January 2005 and December 2011, 1029 consecutive patients who were treated for ULM lesion with DES (1st DES; 765 patients and 2nd DES; 264 patients) were enrolled in this study. The study end point was major adverse cardiac events (MACE) defined as a composite of cardiac death, nonfatal myocardial infarction (MI) and target lesion revascularization (TLR). Furthermore, TLR for main branch (TLR-MB) including ULM itself and proximal Left anterior descending artery and TLR for side branch (TLR-SB) including atostal left circumflex artery alone were evaluated.

Results: Baseline clinical and angiographic characteristics were similar between the two groups. At 1-year, MACE were not different between the 2 groups (16.8±1.4% in the 1st DES vs. 12.2±2.0% in the 2nd DES, HR: 0.924, 95%CI, 0.686–1.244, p=0.601). The occurrence of TLR-MB was similar (6.0%±0.9 vs. 4.7%±1.3%, respectively, HR: 0.785; 95%CI 0.446–1.381, p=0.401). However, 2nd DES were associated with a lower occurrence of TLR-SB as compared to 1st DES (10.4±1.1% versus 6.3±1.5%, respectively, adjusted HR 0.601; 95% CI, 0.411–1.034, p=0.069).

Conclusions: This study suggests that there were not statistically significant improvements between 1st or 2nd DES, concerning mortality and TLR-MB in patients undergoing PCI for ULM disease. However, usage of 2nd DES may contribute to reduce of TLR-SB.

TCT-28
Emergency Percutaneous Coronary Intervention For Unprotected Left Main Coronary Artery Occlusion

Niket Patel1, Derrick Bennett2, Kazem Rahimi2, Peter Ludman3, Adrian Banning4, Robert J. Gil1, Dobrin Vassilev2, Jacek Bil3, Luis A. Iñigo-García4

Background: Limited data exists about the incidence, management and outcomes following presentation with emergency left mainstem coronary artery occlusion (LMSO).

Methods: We searched the national British Cardiovascular Intervention Society database of all Primary PCI cases in the UK from January 2007 to December 2011. Patients’ vital status was obtained through linkage with the national death register.

Results: During the observation period, 1139 patients presenting with ST elevation underwent PPCI to unprotected LMSO (1.5% of PPCI). Information on TIMI flow and severity of occlusion was available in 785 (mean age 69 years). 328/785 patients presented with LMSO (TIMI flow 0/1 and stenosis >75%) and were more likely to be male (75% vs 67%, p=0.02) and less likely to have a history of MI (16% vs 22%, p=0.03). LMSO presentation was associated with a doubling in risk of peri-procedural cardiogenic shock (38% vs 29%, p=0.001) and a larger proportion of patients required inotropic or mechanical circulatory support (p<0.001). 40% of patients with LMSO died during the hospital admission compared with 19% of those who did not present with occlusion (p<0.001). This difference in outcomes was only partly explained by the higher shock rate (see Figure). There was no evidence to suggest that death rates continued to diverge in those with or without LMSO beyond 30 days of follow-up (43% vs 21% and 55% vs 32% for 30-day and 1-year mortality, respectively).

Conclusions: In this largest cohort of patients presenting with LMSO and undergoing PPCI, acute outcomes are predictably poor but long-term outcomes for survivors are encouraging.

TCT-29
First-in-Man Study of Dedicated Bifurcation Sirolimus-Eluting Stent BioSS LIM

Robert J. Gil1, Dobrin Vassilev2, Jackie Bil3, Luis A. Higo-Garcia4

Background: The aim of this prospective, international, first-in-man study is to assess effectiveness and safety of dedicated bifurcation sirolimus-eluting stent BioSS LIM (Balton, Poland) in patients with stable coronary artery disease (CAD) and NSTE-ACS.

Methods: Between October 2011 and October 2012 patients with CAD or NSTEMI who signed informed consent were included into the study. The enrollment was